At last week’s World Economic Forum (WEF) meeting in Davos, Moderna CEO Stéphane Bancel declared he would “like to have mRNA capacity on every continent.” His remark at the annual gathering of global elites should come as no surprise. After all, the pharmaceutical giant has been developing mRNA gene-editing technology for the Defense Advanced Research Projects Agency (DARPA) for over a decade. Still, to test things out on a large scale, the duo lacked “the need and the opportunity.” Two years ago, in an extraordinary windfall for Moderna (and Pfizer), the COVID-19 pandemic provided the perfect fast-tracked opportunity to introduce novel mRNA technology to the masses. Without question, introducing mRNA protein encoding around the planet has driven the strategic plans of both DARPA—a covert agency of the U.S. Department of Defense—and Moderna for over twelve years.
Still, for those not familiar with or currently regulated by the Pfizer-controlled mainstream news, awareness of the backstory is essential to ensure the planet’s future. Reminders of the narrative at play are necessary; thus, a brief rundown of how we got here seems in order.
Years before the COVID-19 pandemic, DARPA, along with its ADEPT: PROTECT program and its $96 million Pandemic Prevention Platform (P3), has been on a secret mission to find a way to develop an antibody for any virus in the world within sixty days of receiving the blood sample from a survivor. Under the guise of “national security,” DARPA’s vision for rapid development of mRNA treatments is shared by its partner Moderna and its CEO Bancel.
On September 12, 2019, in an interesting and timely affirmation of its efforts, Moderna announced—with DARPA’s support—it had reached a “significant scientific breakthrough” in mRNA protein-making technology formulated within its proprietary LNP delivery system. The breakthrough came precisely three months before a cluster of patients in China “began to experience symptoms of an atypical pneumonia-type illness that does not respond well to standard treatments,” and one month before the pandemic practice drill called Event 201, sponsored by the WEF, Johns Hopkins, and Bill Gates. Conveying its positive study results and “validating” DARPA’s “nucleic-acid-based technologies for infectious disease,” Moderna’s announcement stated:
“These Phase 1 data represent a significant scientific breakthrough: this study shows for the first time the ability to generate therapeutic levels of a complex protein in humans through systemic administration of an mRNA, essentially instructing the body to make its medicines.
These exciting data demonstrate a new way to address infectious diseases that uses mRNA to make antibodies in humans, establishing a powerful technology that could be deployable in a pandemic setting.”
On March 11, 2020, six months later, thanks to a declaration by the WHO (funded by Bill Gates), humanity was imperiled by a global pandemic and subsequently thrust into a panic. Suddenly, DARPA (and, to a greater extent, the global elite) was presented with a long-awaited “need and opportunity” to put its development strategy into action. As if right on queue, on March 17, 2020, Moderna and Anthony Fauci’s research crew at NIAID began the first human trials of its mRNA-1273 vaccine against COVID-19. The jab incorporated a novel (and dangerous) “lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.”
With uncanny foresight, Moderna’s expeditious mRNA endeavor (soon to be fully integrated with Artificial Intelligence) had immediate manufacturing support from the Coalition for Epidemic Preparedness Innovations (CEPI) to ensure the pandemic’s gene-editing jabs traversed the globe. Significantly, CEPI was founded in 2017 by the WEF, the Bill & Melinda Gates Foundation, Wellcome, and the governments of Norway and India. Aligned with the same goals as DARPA, CEPI is a global syndicate of public-private organizations whose mission is to highlight pandemic threats, continuously prepare for the next “Disease X,” and advance vaccines.
Presently, over 13 billion doses of COVID-19 Vaccines have been administered worldwide. With vaccine manufacturers protected from liability, evidence increasingly indicates that mRNA injections are not just failing but, more significantly, are causing many serious adverse events, including myocarditis, increased risk of cancer and stroke, and death.
In a recent appearance on The Highwire, Dr. Ryan Cole explained why mRNA injections can be so dangerous. Simply put, human cells are meant to make human proteins, not the foreign spike protein mRNA jabs program our cells to make. According to Dr. Cole, the mRNA platform has proven to be so dangerous that not only do COVID vaccines need to be halted immediately, but the entire experimental platform—and the agencies that have taken it upon themselves carte blanche to keep pushing it forward (like Moderna and DARPA)—need to be stopped. But unfortunately, despite the alarms, stopping mRNA appears unlikely. Instead, with comments like Bancel’s, it is obvious that Big Pharma and the burgeoning public-private partnerships with influence inside Big Government are not stopping. Make no mistake, Moderna’s future squarely rests on developing mRNA treatments. The company currently has a whopping 48 products in its pipeline and over 35 ongoing clinical trials for mRNA treatments for ailments, including infectious diseases, immuno-oncology, personalized cancer vaccines, cardiovascular disease, autoimmune diseases, and rare diseases.
Screenshot / Moderna 2022 Shareholder Letter / Moderna mRNA pipeline
And to make sure the company’s mRNA product list continues to flourish worldwide, Moderna announced its Global Public Health Strategy and mRNA Access program on March 7, 2022. Noting that the COVID-19 pandemic “will not be our last,” mRNA Access invites researchers worldwide to partner with Moderna to “explore the possibility of mRNA for the benefit of global health.” Armed with “equity awareness” and the fear of the next pandemic, the strategy commits Moderna to “advance vaccines targeting 15 pathogens identified as [the] biggest public health risk by WHO and CEPI into clinical studies by 2025.”
Bancel’s blunt forewarning of mRNA’s global invasion should shock no one. Despite a looming snag with Pfizer over its mRNA technology platform, Moderna has spent years preparing for this moment. Last month, along with global partnerships focused on expanding mRNA technology in Belgium, Denmark, the Netherlands, Norway, Poland, Sweden, and Canada, Moderna cemented a 10-year partnership with the U.K. government. Likewise, the company is actively talking with China about supplying the country with its mRNA products.
Indeed, mRNA is not going away. Instead, it is the holy grail of the global elite, opening the door to implementing technology to overcome sickness. Some call that a giant step towards transhumanism. For Moderna, its one-sentence mission statement conveys the company’s explicit, full-speed-ahead international goal: “Our mission is to deliver the greatest possible impact to people through mRNA medicines.”
55,389 total views, 6,455 views today